Meera Chappidi, MD, MPH
ASST PROF IN RES
Urology
School of Medicine

Education & Training

Show all (3) Hide

• M.D. Medicine The Johns Hopkins School of Medicine 05/2017
• M.P.H. Epidemiology & Biostatistics The Johns Hopkins School of Public Health 05/2016
• Sc.B Neuroscience, Economics Brown University 05/2012

Publications (42)

Top publication keywords:
Prostate-Specific AntigenHematuriaUreteral NeoplasmsHospital CostsNomogramsBCG VaccineInsurance Claim ReportingProstateUrinary Bladder NeoplasmsProstatic NeoplasmsCystoscopyWatchful WaitingPatient ReadmissionProstatectomyCystectomy

• Role of MRI in Active Surveillance of Prostate Cancer.
  Seminars in ultrasound, CT, and MR 2024 Chappidi MR, Lin DW, Westphalen AC
• Editorial Comment.
  The Journal of urology 2024 Chappidi MR, Lin DW, de la Calle CM
• Editorial Commentary.
  Urology practice 2024 Chappidi MR, de la Calle CM
• Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.
  Clinical genitourinary cancer 2024 Chappidi MR, Iravani A, Stambler N, Baskaran S, DiPippo VA, Denes BS, Lin DW
• Editorial Commentary.
  Urology practice 2024 Chappidi MR, Gore JL

Show all (37 more) Hide

• Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
  European urology oncology 2023 Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR
• Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols.
  Urologic oncology 2023 Chappidi MR, Escobar D, Meng MV, Washington SL, Porten SP
• Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort.
  The Journal of urology 2022 Shee K, Washington SL, Cowan JE, de la Calle CM, Baskin AS, Chappidi MR, Escobar D, Nguyen HG, Cooperberg MR, Carroll PR
• The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
  The Journal of urology 2022 Chappidi MR, Bell A, Cowan JE, Greenberg SA, Lonergan PE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR
• Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
  The Journal of urology 2021 Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, Lotan Y, Porten SP, Kates M
• Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study.
  JNCI cancer spectrum 2021 Marrone MT, Mondul AM, Prizment AE, Couper D, Barber JR, Chappidi MR, Joshu CE, Platz EA
• The erector spinae plane block can facilitate outpatient stone surgery by reducing breakthrough pain.
  BJU international 2021 Yang H, Lee HH, Martin-Tuite P, Chappidi M, Bowman M, Hamouche F, Ahn J, Stoller M, Braehler M, Chi T
• Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort.
  Urology 2021 Chappidi MR, Welty C, Choi W, Meng MV, Porten SP
• Live Renal Ultrasonography Facilitates Double-J Ureteral Stent Insertion at the Bedside: A Pilot Study for the COVID-19 Era.
  Journal of endourology 2020 Yang H, Chappidi M, Overland M, Ahn J, Bayne D, Chi T
• Cost-Benefit Analysis of a Support Program for Nursing Staff.
  Journal of patient safety 2020 Moran D, Wu AW, Connors C, Chappidi MR, Sreedhara SK, Selter JH, Padula WV
• Urethral Defect in Setting of Recurrent Urethral Foreign Body Insertion.
  Urology 2019 Simms A, Chappidi M, Yang H, Hampson L, Breyer B, Cohen AJ
• Reply by Authors.
  The Journal of urology 2019 Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ
• A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.
  The Journal of urology 2019 Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ
• Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.
  World journal of urology 2019 Brant A, Daniels M, Chappidi MR, Joice GA, Sopko NA, Matoso A, Bivalacqua TJ, Kates M
• Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
  World journal of urology 2019 Gupta M, Milbar N, Tema G, Pederzoli F, Chappidi M, Kates M, VandenBussche CJ, Bivalacqua TJ
• Factors associated with red blood cell, platelet, and plasma transfusions among inpatient hospitalizations: a nationally representative study in the United States.
  Transfusion 2018 Goel R, Patel EU, White JL, Chappidi MR, Ness PM, Cushing MM, Takemoto CM, Shaz BH, Frank SM, Tobian AAR
• Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?
  BJU international 2018 Joice GA, Chappidi MR, Patel HD, Kates M, Sopko NA, Stimson CJ, Pierorazio PM, Bivalacqua TJ
• Trends in Red Blood Cell, Plasma, and Platelet Transfusions in the United States, 1993-2014.
  JAMA 2018 Goel R, Chappidi MR, Patel EU, Ness PM, Cushing MM, Frank SM, Tobian AAR
• Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.
  Bladder cancer (Amsterdam, Netherlands) 2017 Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, Pierorazio PM, Schoenberg MP, Bivalacqua TJ
• High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer.
  Bladder cancer (Amsterdam, Netherlands) 2017 Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ
• Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors.
  The journal of sexual medicine 2017 Pederzoli F, Chappidi MR, Collica S, Kates M, Joice GA, Sopko NA, Montorsi F, Salonia A, Bivalacqua TJ
• Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
  BJU international 2017 Tosoian JJ, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T, Ross AE
• Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.
  BJU international 2017 Chappidi MR, Kates M, Tosoian JJ, Johnson MH, Hahn NM, Bivalacqua TJ, Pierorazio PM
• Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database.
  The journal of sexual medicine 2017 Chappidi MR, Kates M, Sopko NA, Joice GA, Tosoian JJ, Pierorazio PM, Bivalacqua TJ
• Prostate Health Index density improves detection of clinically significant prostate cancer.
  BJU international 2017 Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Mamawala M, Agostino J, Carter HB, Partin AW, Sokoll LJ, Ross AE
• Author Reply.
  Urology 2017 Chappidi MR, Kates M, Bivalacqua TJ
• Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
  Prostate cancer and prostatic diseases 2017 Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE
• Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer.
  Urology 2017 Chappidi MR, Kates M, Brant A, Baras AS, Netto GJ, Pierorazio PM, Hahn NM, Bivalacqua TJ
• Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy.
  The Journal of urology 2016 Matulewicz RS, Tosoian JJ, Stimson CJ, Ross AE, Chappidi M, Lotan TL, Humphreys E, Partin AW, Schaeffer EM
• Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy.
  Urologic oncology 2016 Chappidi MR, Chalfin HJ, Johnson DJ, Kates M, Sopko NA, Johnson MH, Liu JJ, Frank SM, Bivalacqua TJ
• Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
  Urologic oncology 2016 Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, Netto GJ, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ
• Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care.
  The Journal of urology 2016 Chappidi MR, Kates M, Stimson CJ, Johnson MH, Pierorazio PM, Bivalacqua TJ
• Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
  BJU international 2016 Tosoian JJ, Chappidi M, Feng Z, Humphreys EB, Han M, Pavlovich CP, Epstein JI, Partin AW, Trock BJ
• Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012).
  Urologic oncology 2016 Chappidi MR, Kates M, Johnson MH, Hahn NM, Bivalacqua TJ, Pierorazio PM
• Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative Sample.
  The Journal of urology 2016 Chappidi MR, Kates M, Stimson CJ, Bivalacqua TJ, Pierorazio PM
• Accuracy of urethral frozen section during radical cystectomy for bladder cancer.
  Urologic oncology 2016 Kates M, Ball MW, Chappidi MR, Baras AS, Gordetsky J, Sopko NA, Brant A, Pierorazio PM, Epstein JI, Schoenberg MP, Bivalacqua TJ
• Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy.
  Urologic oncology 2016 Chappidi MR, Kates M, Patel HD, Tosoian JJ, Kaye DR, Sopko NA, Lascano D, Liu JJ, McKiernan J, Bivalacqua TJ